Ulf Forssmann

Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors

Volker Lennerz, Elisa Gallerani, Cristiana Sessa et al. · Cancer Immunology Immunotherapy · 2014 · 126 citations · Full text

Medicine, Immunology, Oncology +16

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik, Elena Garralda, Friederike Gieseke et al. · Cancer Discovery · 2022 · 113 citations · Full text

Life Sciences, Immunology, Oncology +17

Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism

Marije B. Overdijk, Kristin Strumane, Frank J. Beurskens et al. · Molecular Cancer Therapeutics · 2020 · 58 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Ágnes Ruzsa, Mehmet Şen, Mark D. Evans et al. · Investigational New Drugs · 2014 · 57 citations

Medicine, Oncology, Cancer Pharmacology +9

Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer

Louise A. Koopman, Mikkel G. Terp, Gijs G. Zom et al. · JCI Insight · 2019 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17